Markers of hemostasis and inflammation in brucellosis infection
Abstract
Annotation. The relevance of the problem of brucellosis infection at the present stage determines the need to continue vector research to study the pathogenesis of the disease, including markers of inflammation and hemostasis, and the processes of development of endothelial dysfunction.
The object of the study was patients diagnosed with acute brucellosis who were undergoing inpatient treatment in an infectious diseases hospital.
The purpose of the study is to determine the level of markers of inflammation and hemostasis: coagulation factors (XII, X, V, II), endothelin-1, nitric oxide and its metabolites (nitrites (NO2-/nitrates (NO3-)), von Willebrand factor, vasculoendothelial factor, in the serum/blood plasma of patients with acute brucellosis and identification of a pathophysiological connection with the possible development of endothelial dysfunction.
Results. An increase in the synthesis of vasculoendothelial factor (344.7±6.8 IU/ml), endothelin-1 (3.89±0.24 pg/ml), nitric oxide and its metabolites (nitrites (NO2- 207.4±11, 0 µmol/l; nitrates (NO3 - 170.9±10.2 µmol/l), (p≤0,001), indicating endothelial dysfunction. A decrease in plasma-coagulation factors of hemostasis was noted in patients with acute brucellosis (factor XII concentration was 50.6±14.0 %; factor X 50.4±13.1%; factor V 38.8±11.0%; factor II 60.9±14.5% compared to the control group, (p≤0,05)), which is possibly due to a protective reaction that prevents thrombus formation and bleeding, but leading to disruption of the maintenance of endothelial cell homeostasis - a “containment strategy” – a protective and adaptive reaction aimed at reducing the intensity of the systemic inflammatory response.
Downloads
References
1. Schastlivtsev I.V., Lobastov K.V., Tsaplin S.N., Mkrtychev D.S. A modern view of the hemostasis system: cellular theory. Meditsinskiy sovet. 2019; (16): 72-77. doi: 10.21518/2079-701X-2019-16-72-77 (in Russian).
2. Makurina O.N. Hemocoagulation mechanisms. Uspekhi sovremennogo yestestvoznaniya. 2015; 5: 76-79 (in Russian).
3. Clinical recommendations «Brutsellez u detey i vzroslykh», St. Petersburg: MOO "AVISPO; 2020. 63 с. (in Russian).
4. Chourmouzi D., Boulogianni G., Kalomenopoulo M., Kanellos I., Drevelegas A. Brucella liver abscess; imaging approach, differential diagnosis, and therapeutic management: a case report. Cases Journal. 2009; 2: 7143.
5. Blood clotting factor X. Available at: https://ru.wikipedia.org/wiki/ (accessed: 21 November 2023).
6. Blood clotting factor V. Available at: https://ru.wikipedia.org/wiki/ (accessed: 21 November 2023).
7. Thrombin. Available at: https://ru.wikipedia.org/wiki/ (accessed: 21 November 2023).
8. Blood clotting factor XII. Available at: https://ru.wikipedia.org/wiki/ (accessed: 21 November 2023).
9. Reshetnyak V.I., Mayev I.V., Reshetnyak T.M., Zhuravel' S.V., Pisarev V.M. Liver diseases and hemostasis (review). Part I. Non-cholestatic liver diseases and hemostasis. Obshchaya reanimatologiya. 2019; 15(5): 74-87 (in Russian).
10. Blood clotting factors. Available at: https://ru.wikipedia.org/wiki/ (accessed: 21 November 2023).
11. Mailer R.K., Rangaswamy C., Konrat S., Emsley J., Renné T. An update on factor XII-driven vascular inflammation. Biochim. Biophys. Acta Mol. Cell Res. Review. 2022; 1869(1):119166. doi: 10.1016/j.bbamcr.2021.119166.
12. R.M. Camire. Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics. Review J. Thromb. Thrombolysis. 2021; 52(2): 383-390. doi: 10.1007/s11239-021-02456-w.
13. Strugov V.V. Congenital deficiency of factor X. Genokarta Geneticheskaya entsiklopediya. 2020. Available at: https://www.genokarta.ru/disease/Vrozhdennyj_deficit_faktora_X. (accessed: 21 November 2023) (in Russian).
14. Menegatti M., Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009; 35(4): 407–415. doi:10.1055/s-0029–1225763.
15. Martin K., Ma A.D., Key N.S. Chapter 15 - Molecular Basis of Hemostatic and Thrombotic Diseases. Molecular Pathology (Second Edition). The Molecular Basis of Human Disease. Molecular Pathology, Second Edition. 2018; 1: 277-297.
16. Factor II. Available at: https://www.invitro.ru/analizes (accessed: 21 November 2023).
17. Morrison D.C., Cochrane C.G. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J. Exp. Med. 1974; 140: 797-811.
18. Kenne E., Nickel K.F. , Long A.T., Fuchs T.A., Stavrou E.X., Stahl F.R. et al. Factor XII: a novel target for safe prevention of thrombosis and inflammation. J. Intern. Med. 2015; 278: 571-585.
19. Gragnano F., Sperlongano S., Golia E., Natale F., Bianchi R., Crisci M. et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators of Inflammation. 2017; 2017: 13. Doi 10.1155/2017/5620314. PMC5467347.
20. Siveen K.S., Prabhu K., Krishnankutty R. Kuttikrishnan S., Tsakou M., Alali F.Q. et al. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges. Curr. Vasc. Pharmacol. 2017; 15(4): 339-51.
21. Seri A., Marta D.S., Madalan A., Popescu M., Tiglea A.I., Moldoveanu E. Lipoprotein-associated phospholipase A2, myeloperoxidase and vascular endothelial growth factor - predictors of high vascular risk in respiratory bacterial infections / // J. Med. Life. 2016; 9(4): 429-433.
22. Cosnin D.YU., Gileva O.S., Sivak YE.YU., Daurova F.YU., Gibadullina N.V., Korotin S.V. The content of vascular endothelial growth factor in saliva and blood serum of patients with periodontitis. Klinicheskaya laboratornaya diagnostika. 2019; 64 (1): 663-668 (in Russian).
23. Akbayram S., Dogan M., Akgun C., Peker E., Parlak M., Oner A. F. Disseminated intravascular coagulation in a case of brucellosis // Clinical and Applied Thrombosis/Hemostasis. 2011; 17(6): 567-E230.
